Compare Amgen, Inc. (AMGN) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Raytheon Technologies Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Raytheon Technologies Corp trades at $196.95 (market cap $263.86B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RTX | |
|---|---|---|
Market Cap | $196.12B | $263.86B |
Sector | Health | Industrials |
52-Week High | $388.16 | $212.16 |
52-Week Low | $271.18 | $146.87 |
Enterprise Value | $241.41B | $295.97B |
Dividend Yield | 2.77% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
RTX trades at $195.93, up 0.37% today, with strong technical momentum and bullish analyst sentiment. The company has exceeded earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $1.66. Recent contract wins including a $515 million Navy radar contract and expanded manufacturing capacity in Poland support growth prospects. Operating cash flow improved to $10.57 billion in 2025, while net income margin expanded to 8.03%.
Outlook remains positive with 69% analyst buy ratings and $213 consensus price target, representing 8.7% upside. Key risks include defense budget volatility and elevated P/E ratio of 36.76. Revenue growth trajectory and margin expansion provide fundamental support, though valuation remains premium relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
